WU-NK-201

WU-NK-201 is an investigational memory natural killer (NK) cell therapy being developed for the treatment of solid tumors. It is designed as an allogeneic, off-the-shelf cell therapy product, leveraging the enhanced cytotoxicity and persistence of memory NK cells to target and eliminate cancer cells. The drug is under development by Wugen, a biotechnology company specializing in cell therapies for hematologic cancers and solid tumors. As a memory NK cell therapy, WU-NK-201 aims to overcome limitations seen with conventional NK or T-cell therapies by providing improved tumor infiltration, resistance to immunosuppressive tumor microenvironments, and sustained anti-tumor activity. Its primary indication is for solid tumors.